Quantitative Structure-Cytotoxicity Relationship of Phenylpropanoid Amides by 島田, 智哉子 et al.
ANTICANCER RESEARCH
International Journal of Cancer Research and Treatment
ISSN: 0250-7005
Reprinted from
ANTICANCER RESEARCH 34: 3543-3548 (2014)
Quantitative Structure–Cytotoxicity Relationship 
of Phenylpropanoid Amides
CHIYAKO SHIMADA1, YOSHIHIRO UESAWA2, MARIKO ISHIHARA3, HAJIME KAGAYA2, 
TAISEI KANAMOTO4, SHIGEMI TERAKUBO4, HIDEKI NAKASHIMA4, KOICHI TAKAO5, 
TAKAYUKI SAITO5, YOSHIAKI SUGITA5 and HIROSHI SAKAGAMI1
1Division of Pharmacology and 3Basic Chemistry, Department of Diagnostic and Therapeutic Sciences, 
Meikai University School of Dentistry, Sakado, Saitama, Japan; 
2Department of Clinical Pharmaceutics, Meiji Pharmaceutical University, Noshio, Kiyose, Tokyo, Japan;
4St. Marianna University School of Medicine, Kanagawa, Japan;
5Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan
P.A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, Houston, TX, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
R. C. BAST, Houston, TX, USA
G. BAUER,  Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
Y. BECKER, Jerusalem, Israel
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
D. D. BIGNER, Durham, NC, USA
A. BÖCKING, Düsseldorf, Germany
G. BONADONNA, Milan, Italy
F. T. BOSMAN, Lausanne, Switzerland
G. BROICH, Monza, Italy
J. M. BROWN, Stanford, CA, USA
Ø. S. BRULAND, Oslo, Norway
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA 
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
E. DE CLERCQ, Leuven, Belgium
W. DE LOECKER, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada 
G. TH. DIAMANDOPOULOS, Boston, MA, USA
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
B. FUCHS, Zurich, Switzerland
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
J. H. GESCHWIND, Baltimore, MD, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
R. H. GOLDFARB, Saranac Lake, NY, USA
S. HAMMARSTRÖM, Umea° , Sweden
I. HELLSTRÖM, Seattle, WA, USA
L. HELSON, Quakertown, PA, USA
R. M. HOFFMAN, San Diego, CA, USA
K.-S. JEONG, Daegu, South Korea
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
B. KAINA, Mainz, Germany
P. -L. KELLOKUMPU-LEHTINEN, Tampere,  
Finland
B. K. KEPPLER, Vienna, Austria
D. G. KIEBACK, Riesa (Dresden), Germany
R. KLAPDOR, Hamburg, Germany
U. R. KLEEBERG, Hamburg, Germany
P. KLEIHUES, Zürich, Switzerland
E. KLEIN, Stockholm, Sweden
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
D. W. KUFE, Boston, MA, USA
Pat M. KUMAR, Manchester, UK
Shant KUMAR,  Manchester, UK
M. KUROKI,  Fukuoka, Japan
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umea° , Sweden
H. T. LYNCH, Omaha, NE, USA
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. MITRA, Houston, TX, USA
M. MUELLER, Heidelberg, Germany
F. M. MUGGIA, New York, NY, USA
M. J. MURPHY, Jr., Dayton, OH, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J.L. PERSSON, Malmö, Sweden
S. PESTKA, Piscataway, NJ, USA
G. J. PILKINGTON, Portsmouth, UK 
C. D. PLATSOUCAS, Norfolk, VA, USA
F. PODO, Rome, Italy
A. POLLIACK, Jerusalem, Israel
G. REBEL, Strasbourg, France
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
A. SETH, Toronto, ON, Canada 
G. V. SHERBET, Newcastle-upon-Tyne, UK
G.-I. SOMA, Tokushima, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umea° , Sweden
T. M. THEOPHANIDES, Athens, Greece
B. TOTH, Omaha, NE, USA
P. M. UELAND, Bergen, Norway
H. VAN VLIERBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Duarte, CA, USA
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA
J. G. DELINASIOS, Athens, Greece
Managing Editor
G. J. DELINASIOS, Athens, Greece
Assisrtant Managing Editor and 
Executive Publisher
E. ILIADIS, Athens, Greece
Production Editor
Editorial Board Editorial Office: International Institute of Anticancer Research, 1st km
Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014,
Greece. Tel / Fax: +30-22950-53389.
E-mails: Editorial Office: journals@iiar-anticancer.org
Managing Editor: editor@iiar-anticancer.org
ANTICANCER RESEARCH supports: (a) the establishment and the
activities of the INTERNATIONAL INSTITUTE OF ANTICANCER
RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization
of the International Conferences of Anticancer Research.
For more information about ANTICANCER RESEARCH, IIAR and the
Conferences, please visit the IIAR website: www.iiar-anticancer.org
Publication Data: ANTICANCER RESEARCH (AR) is published monthly
from January 2009. Each annual volume comprises 12 issues. Annual
Author and Subject Indices are included in the last issue of each volume.
ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online
with Stanford University HighWire Press from April 2009.
Copyright: On publication of a manuscript in AR, which is a
copyrighted publication, the legal ownership of all published parts of
the paper passes from the Author(s) to the Journal.
Annual Subscription Rates 2014 per volume: Institutional subscription
Euro 1,650.00 - print or online. Personal subscription Euro 780.00 - print
or online. Prices include rapid delivery and insurance. The complete
previous volumes of Anticancer Research (Vol. 1-33, 1981-2013) are
available at 50% discount on the above rates.
Subscription Orders: Orders can be placed at agencies, bookstores, or
directly with the Publisher. Cheques should be made payable to J.G.
Delinasios, Executive Publisher of Anticancer Research, Athens, Greece,
and should be sent to the Editorial Office.
Advertising: All correspondence and rate requests should be
addressed to the Editorial Office.
Book Reviews: Recently published books and journals should be sent to
the Editorial Office. Reviews will be published within 2-4 months.
Articles in ANTICANCER RESEARCH are regularly indexed in all
bibliographic services, including Current Contents (Life Sciences), Science
Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical
Abstracts, Excerpta Medica, University of Sheffield Biomedical Information
Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic
Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE,
FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge
Scientific Abstracts, Cancergram (International Cancer Research Data
Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-
Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts,
Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts,
Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB
Abstracts/Global Health Databases, Investigational Drugs Database, VINITI
Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad
Iberoamericana de Información Científíca (SIIC) Data Bases.
Authorization to photocopy items for internal or personal use, or the
internal or personal clients, is granted by ANTICANCER RESEARCH,
provided that the base fee of $2.00 per copy, plus 0.40 per page is paid
directly to the Copyright Clearance Center, 27 Congress Street, Salem,
MA 01970, USA. For those organizations that have been granted a
photocopy license by CCC, a separate system of payment has been
arranged. The fee code for users of the Transactional Reporting Service is
0250-7005/2014 $2.00 +0.40.
The Editors and Publishers of ANTICANCER RESEARCH accept no
responsibility for the opinions expressed by the contributors or for the
content of advertisements appearing therein.
Copyright© 2014, Ιnternational Institute of Anticancer Research
(Dr. John G. Delinasios), All rights reserved.
D.T.P. BY IIAR
PRINTED BY ENTYPO, ATHENS, GREECE
PRINTED ON ACID-FREE PAPER
ISSN (print): 0250-7005
ISSN (online): 1791-7530
Abstract. Background: A total of 12 phenylpropanoid amides
were subjected to quantitative structure–activity relationship
(QSAR) analysis, based on their cytotoxicity, tumor selectivity
and anti-HIV activity, in order to investigate on their biological
activities. Materials and Methods: Cytotoxicity against four
human oral squamous cell carcinoma (OSCC) cell lines and
three human oral normal cells was determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
method. Tumor selectivity was evaluated by the ratio of the
mean CC50 (50% cytotoxic concentration) against normal oral
cells to that against OSCC cell lines. Anti-HIV activity was
evaluated by the ratio of CC50 to EC50 (50% cytoprotective
concentration from HIV infection). Physicochemical, structural,
and quantum-chemical parameters were calculated based on
the conformations optimized by the LowModeMD method
followed by density functional theory (DFT) method. Results:
Twelve phenylpropanoid amides showed moderate cytotoxicity
against both normal and OSCC cell lines. N-Caffeoyl
derivatives coupled with vanillylamine and tyramine exhibited
relatively higher tumor selectivity. Cytotoxicity against normal
cells was correlated with descriptors related to electrostatic
interaction such as polar surface area and chemical hardness,
whereas cytotoxicity against tumor cells correlated with free
energy, surface area and ellipticity. The tumor-selective
cytotoxicity correlated with molecular size (surface area) and
electrostatic interaction (the maximum electrostatic potential).
Conclusion: The molecular size, shape and ability for
electrostatic interaction are useful parameters for estimating
the tumor selectivity of phenylpropanoid amides. 
Phenylpropanoid amides, synthesized by coupling reaction
with cinnamic acid derivatives and serotonin or
phenylalkylamines showed antioxidant (1, 2), tyrosinase-
inhibitory activity (2-4), cyclo-oxygenase 2-inhibitory activity
(5), and anti-microbial (6) and anti-fungal activities (7). Due
to their inhibitory action on melanin synthesis and skin
pigmentation, these groups of compounds are useful materials
for cosmetic ingredients, and functional foods (8). However,
the studies of biological activities of phenylpropanoid amides
have been limited to these research areas.
In order to further explore their biological activities, a
total of 12 synthetic phenylpropanoid amides [cinnamic acid
derivatives (p-coumaric acid, ferulic acid and caffeic acid)
coupled with vanillylamine (compounds 1-3), tyramine
(compounds 4-6), dopamine (compounds 7-9) or serotonin
(compounds 10-12)] (Figure 1) were investigated for their
cytotoxicity and anti-HIV activity, and then subjected to
quantitative structure–activity relationship (QSAR) analysis. 
For cytotoxicity assay, both human normal oral cells
(gingival fibroblast, HGF; pulp cells, periodontal ligament
fibroblast, HPLF; pulp cell, HPC) and human oral squamous
cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3,
HSC-4) were used as target cells. The tumor-selectivity index
(TS) was calculated by dividing the mean 50% cytotoxic
concentration (CC50) against normal oral cells by that against
OSCC cell lines. 
For anti-HIV assay, mock- and HIV-infected-human T-cell
lymphotropic virus-I (HTLV-I) carrying human T-cell line
MT4 was used. The selectivity index (SI) was calculated by
diving the CC50 by the 50% cytoprotective concentration
from HIV infection (EC50).
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Materials and Methods
Materials. The following chemicals and reagents were obtained
from the indicated companies: Dulbecco’s modified Eagle’s medium
(DMEM), from GIBCO BRL, Grand Island, NY, USA; fetal bovine
serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), doxorubicin, azidothymidine and 2’, 3’-
dideoxycytidine from Sigma-Aldrich Inc., St. Louis, MO, USA;
dimethyl sulfoxide (DMSO), dextran sulfate (molecular mass, 5
kDa) from Wako Pure Chem. Ind., Osaka, Japan; 5-fluorouracil (5-
FU) from Kyowa, Tokyo, Japan; docetaxel from Toronto Research
Chemicals, NY, USA; curdlan sulfate (molecular mass, 79 kDa)
from Ajinomoto Co. Ltd., Tokyo, Japan. Culture plastic dishes and
plates (96-well) were purchased from Becton Dickinson (Franklin
Lakes, NJ, USA). 
Synthesis of test compounds. N-p-Coumaroylvanillylamine (1), N-
feruloylvanillylamine (2), N-caffeoylvanillylamine (3), N-p-
coumaroyltyramine (4), N-feruloyltyramine (5), N-caffeoyltyramine
(6), N-p-coumaroyldopamine (7), N-feruloyldopamine (8), N-
caffeoyldopamine (9), N-p-coumaroylserotonin (10), N-
feruloylserotonin (11) and N-caffeoylserotonin (12) (Figure 1) were
synthesized by coupling of cinnamic acid derivatives with
vanillylamine, tyramine dopamine, or serotonin in N,N-
dimethylformamide and dichloromethane in the presence of
triethylamine and 1-hydroxy-1H-benzotriazole, and 1-ethyl-3-(3-
dimethyaminopropyl) carbodiimide as a coupling reagent, according
to previous methods (9). All compounds were dissolved in DMSO at
40 mM and stored at –20˚C before use.
Cell culture. HGF, HPLF and HPC cells, established from the first
premolar tooth extracted from the lower jaw of a 12-year-old girl
(10), and OSCC cell lines (Ca9-22, HSC-2, HSC-3, HSC-4),
purchased from Riken Cell Bank, Tsukuba, Japan were cultured at
37°C in DMEM supplemented with 10% heat-inactivated FBS, 100
units/ml, penicillin G and 100 μg/ml streptomycin sulfate under a
humidified 5% CO2 atmosphere. Cells were then harvested by
treatment with 0.25% trypsin-0.025% EDTA-2Na in PBS(−) and
either subcultured or used for experiments.
Assay for cytotoxic activity. Cells were inoculated at 2.5×103 cells/0.1
ml in a 96-microwell plate (Becton Dickinson Labware, NJ, USA).
After 48 h, the medium was removed by suction with aspirator, and
replaced with 0.1 ml of fresh medium containing different
concentrations of single test compounds (0, 3.1, 6.3, 12.5, 25, 50, 100,
200 or 400 μM). Control cells were treated with the same amounts of
DMSO present in each diluent solution (0.0078, 0.0156. 0.03125,
0.0625, 0.125, 0.25, 0.5 or 1%). Cells were incubated for 48 h, and the
relative viable cell number was then determined by MTT method. In
brief, the treated cells were incubated for another three hours in fresh
culture medium containing 0.2 mg/ml MTT. Cells were then lysed with
0.1 ml of DMSO, and the absorbance at 540 nm of the cell lysate was
determined using a microplate reader (Biochromatic Labsystem,
Helsinki, Finland). The CC50 was determined from the dose–response
curve and the mean value of CC50 for each cell type was calculated
from three independent experiments. 
Calculation of TS. The TS was calculated by the following equation:
TS=mean CC50 against normal cells/mean CC50 against tumor cells
ANTICANCER RESEARCH 34: 3543-3548 (2014)
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Table I. Cytotoxic activity of twelve phenylpropanoid amide derivatives. Each value represents the mean±S.D. of triplicate assays.
CC50 (μM)
Human oral squamous cell carcinoma cell Human normal oral cell
Phenylpropanoid Ca9-22 HSC-2 HSC-3 HSC-4 mean±S.D. HGF HPLF HPC mean±S.D. TS
amides (A) (B) (C) (D) (D/B) (C/A)
1 68±39 155±9.4 262±11 218±37 176±8.4 180±25 243±3.8 255±5.5 226±40 1.3 2.6 
2 66±38 229±8.6 238±40 269±60 201±91 207±13 295±11 257±2.9 253±44 1.3 3.1 
3 79±44 94±28 89±10 227±20 122±70 >400 >400 334±42 >378 >3.1 >5.1
4 21±7.5 25±7.3 88±22 53±14 47±31 62±9.9 65±18 51±6.4 59±7.4 1.3 3.0 
5 222±49 274±18 277±7.5 299±11 268±33 211±7.0 220±13 275±29 235±35 0.9 1.0 
6 153±11 45±9.6 74±7.5 126±4.0 100±49 325±73 333±115 >363 >340 >3.4 2.1 
7 261±74 54±6.5 174±29 83±1.5 143±84 269±16 212±12 271±3.6 251±34 1.8 1.0 
8 >400 87±8.7 316±40 272±7.8 268±132 352±54 278±62 320±8.7 317±37 1.2 0.9 
9 361±46 72±25 172±49 221±2.1 207±120 318±12 306±13 322±6.7 315±8.3 1.5 0.9 
10 236±92 74±5.5 122±24 184±5.0 154±71 111±11 146±12 212±24 156±51 1.0 0.5 
11 134±7.8 142±1.0 139±17 181±2.0 149±22 164±5.5 175±2.0 242±7.5 194±42 1.3 1.2 
12 157±16 102±11 139±20 130±4.6 132±23 117±26 117±15 158±3.5 131±24 1.0 0.7 
Positive controls
Docetaxel <0.0078 <0.0078 <0.0078 <0.0078 <0.0078 >1 >1 >1 >1 >128 >128
5-FU 59.4±17.7 12.1±3.1 41.5±10.5 <7.8 30.2±24.6 >2000 >2000 >2000 >2000 >66 >34
Doxorubicin 0.74±0.23 0.22±0.03 0.40±0.11 0.20±0.05 0.39±0.25 1.70±0.47 1.30±0.20 >5.0 2.67±2.0 6.8 2.3 
HGF: Human gingival fibroblast; HPC, pulp cells; HPLF, periodontal ligament fibroblast; Ca9-22, HSC-2, HSC-3, HSC-4: oral squamous cell
carcinoma cell lines; TS: Tumor selectivity index; CC50: 50% cytotoxic concentration; 5-FU: 5-fluorouracil.
[(D/B) in Table I]. Since Ca9-22 cells were derived from gingival
tissue (11), the relative sensitivity of Ca9-22 and HGF was also
compared [(C/A) in Table I]. 
Assay for anti-HIV activity. HTLV-I-carrying human T-cell line MT4
cells, highly sensitive to Human Immunodeficiency Virus-1 (HIV-
1), were infected with HIV-1IIIB at a multiplicity of infection
(m.o.i.) of 0.01. HIV- and mock-infected (control) MT-4 cells were
incubated for five days with different concentrations of samples and
the relative viable cell number was determined by MTT assay. The
CC50 and EC50 were determined from the dose–response curve for
mock-infected and HIV-infected cells, respectively (12). All data
represent the mean values of triplicate measurements. The anti-HIV
activity was evaluated by SI (=CC50/EC50). 
Estimation of CC50 values. Original data contain the sign of
inequality such as”>”. For the convenience of analysis, these values
were changed into forms suitable for arithmetic calculation. Since
“>400” is equal to “from 400 to ∞”, we calculated the harmonic
mean as follows: 1/[average(1/400,1/∞)]=800. Since the CC50 values
had a distribution pattern close to a logarithmic normal distribution,
we used the pCC50 (i.e., the −log CC50) for the comparison of the
cytotoxicity between the compounds. The mean pCC50 values for
normal cells and tumor cell lines were defined as N and T,
respectively (13).
Calculation of the representative value for tumor selectivity. Tumor
selectivity is defined by the balance between pCC50 values for
normal (N) and tumor (T) cells. The difference (T−N) was used for
the following analyses as a tumor-selectivity index.
Calculation of chemical descriptors. Each chemical structure was
optimized by the LowModeMD method (14), a suitable search
method for minimum energy conformers of flexible molecules, with
Merck Molecular Force Field (MMFF94) in Molecular Operating
Environment (MOE) 2013.08 (Chemical Computing Group Inc.,
Quebec, Canada). Each structure was refined with density functional
theory (DFT-B3LYP/6-31G**) by using Spartan10 for Windows
(Wavefunction, Inc., Irvine, CA, USA) (12). During each step of the
calculation, quantum chemical, molecular shape, and molecular
property parameters were obtained. The parameters used were: Gibbs
free energy (G˚), entropy (S˚), enthalpy (H˚), surface area (molecular
surface area), water-accessible polar surface area (acc. visible polar
area), highest occupied molecular orbital (HOMO) energy, lowest
unoccupied molecular orbital (LUMO) energy, hardness (chemical
hardness), ovality (oval ellipticity), lipophilicity (logPo/w), molecular
hydrogen bond acceptor count (HBACount) (i.e. the number of
acceptor atoms), maximum electrostatic potential (MaxElPot).
Statistical treatment. The relation among cytotoxicity, tumor
specificity index, anti-UV activity and chemical descriptors was
investigated using simple regression analyses by JMP Pro version
10.0.2 (SAS Institute Inc., Cary, NC, USA). The significance level
was set at p<0.05.
Results
Cytotoxicity. Twelve phenylpropanoid amides showed
moderate cytotoxicity against both normal human oral cells
and human OSCC cell lines. In most cases, OSCC cells
showed slightly higher sensitivities than normal cells, yielding
weak tumor selectivity (TS=0.9 to >3.4), as compared with
popular chemotherapeutic agents (docetaxel, fluorouracil,
doxorubicin: TS=6.8 to >128) (expressed as D/B in Table I). 
Phenypropanoid/vanillylamine derivatives (1-3) showed
some tumor selectivity [TS=1.3 to >3.1 (D/B), 2.6 to >5.1
(C/A)]. Among them, 3 having a caffeoyl group showed the
highest cytotoxicity (CC50=122 μM) and tumor selectivity
(TS>3.1).
Phenylpropanoid/tyramine derivatives (4-6) showed
comparable tumor selectivity [TS=0.9 to >3.4 (D/B), 1.0 to
3.0 (C/A)]. Among them, 6 having caffeoyl group again
showed the highest tumor-selectivity [TS>3.4 (D/B), 2.1
(C/A)], although 6 showed slightly lower cytotoxicity
(CC50=100 μM) than 4 (CC50=47 μM).
Phenylpropanoid/dopamine (7-9) and serotonin (10-12)
derivatives showed essentially no tumor-selectivity [TS=1.0-
1.8 (D/B), 0.5-1.2 (C/A)], regardless of the presence or
absence of caffeoyl group. 
Anti-HIV activity. In contrast to higher anti-HIV activity of
positive controls (dextran sulfate, curdlan sulfate,
azidothymidine, 2’,3’-dideoxycytidine) (SI=1789-15882),
Shimada et al: QSAR of Phenylpropanoid Amides
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Figure 1. Structure of phenylpropanoid amides. 
none of the phenylpropanoid amides 1-12 were able to
protect the cells from cytopathic effect of HIV infection
(SI<1) (Table II). Based on these data, the following QASR
analysis was focused on the cytotoxicity of phenypropanoid
amides. 
Computational analysis. Cytotoxicity of phenylpropanoid
amides against tumor cells (defined by T) correlated with G˚
(r2=0.367), S˚ (r2=0.495), H˚ (r2=0.367), molecular surface
area (r2=0.442), oval ellipticity (r2=0.387) and HBA count
(r2=0.357) (Figure 2A). 
ANTICANCER RESEARCH 34: 3543-3548 (2014)
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Figure 2. Correlation coefficient of chemical descriptors and cytotoxicity against tumor cells (defined as T) (A) and normal cells (defined as N) (B).
The mean (pCC50 i.e, the −log CC50) values for normal cells and tumor cell lines were defined as N and T, respectively.
On the other hand, cytotoxicity of phenylpropanoid amides
against normal cells (defined by N) was correlated with
water-accessible polar surface area (r2=0362), HOMO energy
(r2=0.381), chemical hardness (r2=0.536), lipophilicity
(r2=0.362) and HBA count (r2=0.287) (Figure 2B). 
Tumor selectivity of phenylpropanoid amides (defined by
T−N) correlated with surface area and the maximum
electrostatic potential (Figure 3). 
Discussion
The present study demonstrated for the first time that
phenylpropenoid amides showed moderate cytotoxicity and
tumor selectivity, but no detectable anti-HIV activity. Among
them, N-caffeoyl derivatives coupled with vanillylamine (3)
and tyramine (6) showed relatively higher tumor selectivity
(Figure 1, Table I), however such higher tumor selectivity
was almost completely eliminated by replacing these amines
with serotonin moiety (12), possibly due to the increase of
surface area or decrease of electrostatic interaction (the
maximum electrostatic potential) (Figure 3). We also found
that phenylpropanoid amides coupled with dopamine (7-9),
having a catechol moiety, had little or no tumor selectivity. 
Previous study with phenylpropanoid amides coupled with
octopamine or dopamine demonstrated that antioxidant
activity, but not tyrosinase-inhibitory activity, depends on the
presence of catechol moiety in the molecule (2). However,
catechols are known to exert both anti-oxidant and pro-
oxidant actions under different experimental conditions (16,
17), and catechol present in the N-caffeoyl moiety of the
same molecule may affect the biological activity.
Phenylpropanoid amides brasiliamide A and B (6), N-p-
coumaroylserotonin and N-feruloylserotonin (7) showed
antimicrobial and antifungal activities, respectively. Recently,
p-coumaric acid derivatives showed potent tyrosinase-
inhibitory activity (4). These data suggest the possibility that
different combinations of phenylpropanoid and
phenylethylamine or phenylmethylamine moieties may
produce totally new biological activities. 
QSAR analysis provided several useful parameters for
estimating the cytotoxicity against normal cells or tumors
cells. Electrostatic interaction-related descriptors such as
polar surface area and chemical hardness may be involved in
the expression of cytotoxicity of phenylpropanoid amides
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Figure 3. Correlation coefficient of chemical descriptors and tumor selectivity, defined as T−N.
Table II. Anti-HIV activity of phenylpropanoid amides and
chemotherapeutic agents. Each value represents the mean of triplicate
determinations. 
Phenylpropanoid amides CC50 (μM) EC50 (μM) SI
1 196.84 >400 <1
2 226.11 >400 <1
3 121.51 >400 <1
4 30.19 >400 <1
5 192.25 >400 <1
6 158.56 >400 <1
7 49.75 >400 <1
8 51.16 >400 <1
9 43.74 >400 <1
10 220.69 >400 <1
11 193.13 >400 <1
12 47.16 >400 <1
Positive controls
Dextran sulfate (μg/ml) 620.5 0.05 12363
Curdlan sulfate (μg/ml) >1000 0.18 >5523
Azidothymidine (μM) 232.87 0.015 15882
2’,3’-Dideoxycytidine (μM) 2145.33 1.2 1789
CC50: 50% Cytotoxic concentration; EC50: 50% effective concentration;
SI: selectivity index (CC50/EC50). 
against normal cells, whereas free energy, surface area and
ellipticity may affect cytotoxicity against tumor cells. This
suggests that the molecular size, shape and electrostatic
interaction may be involved in cytotoxicity induction by
phenylpropanoid amides. 
In conclusion, the present study demonstrates there are
many chemical descriptors specific to T or N. Multivariate
statistics with these chemical descriptors may be useful for
estimation of tumor selectivity.
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